1. Introduction {#sec1}
===============

The renin-angiotensin system (RAS) plays important roles in the regulation of electrolytes, blood pressure (BP), and atherosclerosis \[[@B1]\]. Renin catalyzes the first and rate limiting step of the cascade, the conversion of angiotensinogen to angiotensin I \[[@B2]\]. Genetic variants of this system have been developed to test their association with cardiovascular and renal condition \[[@B3]\]. It has been reported that genetic variant*REN* of C-5312T might be functional and lead to changing renin transcriptions in hypertensive patients. Increased renin gene transcription may increase the concentration of renin in the circulation thereby increasing the activation of the renin-angiotensin system \[[@B4], [@B5]\].

Angiotensin receptor blockers are the treatment of hypertension based RAS blockade where a number of large-scale prospective studies have proven that this medication have favorable effects of cardiovascular and renal conditions. Our previous study in Saiful Anwar outpatient clinic revealed that 42% of hypertensive patients were treated by ARB whereas only 21.8% of the patients achieved the blood pressure target \[[@B6]\]. These facts rise an intriguing question whether the variety of ARB therapy response exists among hypertensive patients.

Previous study has suggested that genetic variant*REN* C-5312T significantly resulted in an increase of plasma renin activity (PRA) on 3 months\' ARB administration Japanese hypertensive patients \[[@B7]\]. However, the presence of renin genetic variants and their effect on Indonesian hypertensive patients and serum renin levels response to ARB remain unclear. Hence, this study was conducted to investigate the presence of renin genetic variants on enhancer region of rennin gene and their effect on renin serum level after ARB administration.

2. Material and Methods {#sec2}
=======================

This study was conducted in RSUD Dr. Saiful Anwar Malang during July--December 2014. Adult hypertensive patients with creatinine \< 2.5 mg/dL and good medication adherence were recruited. Antihypertensive medication adherence was measured by Morisky Medication Adherence Score (MMAS) \[[@B8]--[@B10]\]. Compliance and blood pressure were observed during 5 months of follow-up. Then salt intake was assessed by Food Frequency Questioner (FFQ) \[[@B11]\].

Hypertensive patients with massive bleeding, hepatic failure, renal failure, pregnancy, and known estrogen/corticosteroid therapy were excluded from this study. Blood samples were collected at the baseline and after receiving valsartan (25 patients) and telmisartan (30 patients) at least for 5 months. Renin serum was assayed by indirect ELISA method.

2.1. Genetic Variant Analysis {#sec2.1}
-----------------------------

Genomic DNA samples were isolated using a DNA extraction kit (Geneaid). Renin gene amplification was assayed by multiplex PCR with the followingprimers sense oligo 5′-CGT AGT GCC ATT TTT AGG AAC′-3′ and antisense oligo 5′-AAC ACC AAA GCA GGC-3′ \[[@B4]\] with additional primers originally designed by us from the adjacent sequence \[[@B17]\], which were the following: sense oligo 5′-GCA GTC TCT GTA AGT GCC AC-3′ and antisense oligo 5′-CCA AAG CAG GCT TAA TCT CA-3′. The program consisted of 35 cycles of denaturation at 95°C temperature for 30 seconds, annealing at a temperature gradient 48--58°C for 30 seconds and extension at 72°C for 1 min followed by a final extension at 72°C for 10 minutes.

2.2. Statistical Analysis {#sec2.2}
-------------------------

Phenotypic data are expressed as mean ± SD, as median \[interquartile range\], or as numbers (percentages). The differences between two paired continuous variables in genotype CC and genotype CT/TT were analyzed by paired *t*-test. The differences of renin levels between genotypes CC and CT/TT renin gene were analyzed by unpaired *t*-test. And the differences of characteristic baseline between two genotypes groups were assased by chi-square test as appropriate with considered significant value *P* \< 0.05.

3. Results {#sec3}
==========

3.1. Genetic Variants of*REN* C-5312T and Baseline Characteristic {#sec3.1}
-----------------------------------------------------------------

A total of 55 subjects received monotherapy with valsartan or telmisartan for 5 months and completed the study. The baseline demographic, clinical, and biochemical characteristics of the subjects were almost balanced among genotypes of*REN* C-5312T. The distributions of genotypes for these SNPs were all in Hardy--Weinberg Equilibrium. From the above baseline characteristics significant differences of age, history of hypertension, BMI, dietary salt, urea, and creatinine levels between genotype CC and CT/TT were not found ([Table 1](#tab1){ref-type="table"}). However, females more frequently have TT/CT genotype (*P* = 0.008) ([Table 1](#tab1){ref-type="table"}).

3.2. Genotype Frequency of Renin C-53212T {#sec3.2}
-----------------------------------------

DNA amplification product of the renin gene C-5312T carried by PCR multiplex was then tested qualitatively using 1.5% agarose ([Figure 1](#fig1){ref-type="fig"}). The results of the multiplex PCR analysis on 55 samples showed that the respondents with CT/TT genotypes (64.3%) are larger than respondents with CC genotypes (35.7%) and further analysis used chi-square test with significant difference found between two genotypes frequencies (*P* = 003).

3.3. Association of Renin Levels of C-5312T and ARB Therapy in Hypertensive Patients {#sec3.3}
------------------------------------------------------------------------------------

Renin levels results were obtained from measurements of serum hypertensive patients with indirect Elisa method. The result showed that there was a difference in the changes of renin levels in C-5312T genotypes in response to telmisartan and valsartan therapy. CT/TT genotype has a higher increase (10 pg/mL) of renin levels than CC genotype (4.06 pg/mL) after 5 months of telmisartan therapy, but not valsartan, as shown in Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}.

3.4. Genetic Variants of C-5312T*REN* and Reduction in Blood Pressure with ARB {#sec3.4}
------------------------------------------------------------------------------

Changes in blood pressure genetic variation of C-5312T*REN* are summarized in Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"}. Among the 55 hypertensive patients, changes in diastolic blood pressure (DBP) were significantly different according to the genetic variant of renin C-5312T in response to telmisartan and valsartan therapy. This result showed that the reductions in DBP in CC genotype were significantly larger (10 mmHg) than CT/TT genotype (15.3 mmHg) in hypertensive patients after 5 months of valsartan therapy. CC genotype also showed a larger reduction of DBP (8 mmHg) than CC/TT genotype (12 mmHg) in hypertensive patients after 5 months of valsartan therapy.

3.5. Association of Renin Levels of C-5312T and Salt Intake in Hypertensive Patients {#sec3.5}
------------------------------------------------------------------------------------

It is known that salt is one of the important elements in the regulation of renin secretion, so in this study, we analyzed the differences of renin levels in hypertensive patients with nonsalt diet and dietary salt. This study shows that renin levels in patients with salt diet were higher than patients with nonsalt diet (*P* = 0.021) (Tables [6](#tab6){ref-type="table"} and [7](#tab7){ref-type="table"}). This result proves that salt is a regulator of renin secretion \[[@B11], [@B12]\].

Then to determine the difference of renin levels between CT/TT genotypes and CC genotypes based on salt intake and its responses to early ARB therapy, we analyzed the differences of renin levels between genotype CC and CT/TT in patients with salt dietary. From the analysis we obtained that renin levels of genotype CT/TT were significantly higher than CC genotype in patients with salt dietary. It is suggested that CC genotype is a predictor responder ARB in early therapy.

4. Discussion {#sec4}
=============

In the RAS system, renin is the main enzyme activation system that started this. Renin gene has a major role in controlling blood pressure. Renin catalyzes the first and rate limiting step of the cascade, the conversion of angiotensinogen to angiotensin I \[[@B2], [@B13], [@B14]\]. Renin gene transcription level is influenced by many factors such as the presence of distal enhancers renin gene and the presence of polymorphisms in the area. Several studies have identified SNPs in genes related to the renin hypertension \[[@B14]--[@B16]\]. Previous research reported that the renin gene polymorphism at position C-5312T area renin gene enhancer affects the renin gene expression. Fuchs et al. revealed that variant genetic renin gene -5312T increases renin gene transcription level of 45% in comparison with genotype -5312C.

There are three transcription factors that are identified in the renin gene enhancers including NRF-2, Sp1, and AP-1. All three proteins may be regarded as a functional transcription factor in the renin gene enhancer. This is evidenced from previous research by Germain et al. (1998) which revealed that the binding of AP-1 by binding its site can initiate transcription of the renin gene enhancer \[[@B16]\]. Similarly, the presence of mutations or deletions in the site NRF-2 can reduce the activity of the renin gene transcription enhancers as much as 89%, whereas mutations in the Sp1 sites can reduce the activity of the renin gene transcription by 40% \[[@B18], [@B19]\]. Transcription factor SP-1 also has the same consensus with genetic variants renin -5312C and -5312T. Activation of this transcription factor is influenced by several factors including the binding of angiotensin II (Ang-II) with AT1R which can be activated by several signaling and MAPK pathways. This pathway can induce phosphorylate coactivator of Nrf2, AP-1, and SP-1 transcription factor to initiate*REN* gene basal transcriptions \[[@B20]\].

The therapeutic effect may be supported by the presence of AT1R signaling blockade, where this signaling can inhibit the MAPK pathway, and activation of transcription factor (SP-1, AP-1, and Nrf2). In this study a significant difference in the change in renin levels was found in early therapy and after therapy between CC genotype and genotype CT/TT. CT/TT genotype has a higher increase of renin levels than CC genotype. This may be caused by the change from C to T base renin gene enhancer-5312 position, which can increase transcription factor binding to its binding site. A previous study analyzed the pattern of binding of transcription factor SP-1 to site*REN* gene enhancer-5312, proving that the binding energy is greater on the T allele than the C allele.

Previous study also showed that genetic variant of renin contributes to BP variation in a Caucasian population. Carriers of the renin -5312T allele had higher systolic and diastolic BP in hypertensive patients on 3 months of ARB therapy. This study suggested that CC genotype is a predictor responder ARB therapy. However, it is widely known that ARB causes a negative feedback mechanism in renin release. Angiotensin receptor blocker (ARB) acts as an antagonist AT1 receptor that prevents binding of angiotensin II to AT1 receptor, which acts as inhibition of renin production by juxtaglomerular cells in the kidney. The admission of ARB causes the loss of stimulation of AT1 receptors on juxtaglomerular cells that initiate negative feedback to improve the activity of the renin which can increase plasma renin activity and also increase formation of angiotensin I.

5. Conclusion {#sec5}
=============

In this study it was indicated that CT/TT genotype has a significantly higher renin levels than CC genotype (*P* = 0.025). Then, the reductions of DBP in C allele homozygotes were significantly larger than those in T allele carriers in hypertensive patients after 5 months of valsartan or telmisartan treatment. These findings suggested that SNP of C-5312T*REN* enhancer might contribute to higher increased renin serum levels and less diastolic blood pressure response to ARB treatment.

Limitations {#sec6}
===========

Several limitations of this study should be noted. The sample size we have used is still relatively small to represent generalization of Indonesian population. Other genetic and nongenetic factors that can influence renin levels are not evaluated in this study.
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###### 

Baseline characteristic of hypertensive patients.

  Variable                                     TT/CT           CC              *P*
  -------------------------------------------- --------------- --------------- ------------
  Age, years                                   58.6 ± 9.17     54.5 ± 7.64     0.062
  Sex, *n* (%)                                                                  
   Male                                        15 (41.6)       15 (78.9)       0.008^*∗*^
   Female                                      21 (78.9)       4 (21.1)        
  Duration of suffering hypertension, months   84.86 ± 42.06   64.80 ± 78.85   0.578
  BMI                                          27 (3.46)       26,2 (4.19)     0.496
  Salt diet                                                                     
   Yes                                         13 (68.4)       20 (55.5)       0.138
   No                                          7 (36.8)        16 (44.4)       
  Creatinine, mg/dL                            1.08 ± 0.27     1.01 ± 0.28     0.40
  Urea, mg/dL                                  26 ± 4.75       30.3 ± 15.1     0.22

Data are means ± SD or medians (interquartile ranges). ^*∗*^The differences between baseline characteristic variables for genotypes CC and CT/TT were analyzed by chi-square test as appropriate.

###### 

Differences of renin levels (telmisartan therapy).

  Variable        Genotypes       *P* value       
  --------------- --------------- --------------- ------------
  Early therapy   37.32 ± 9.04    37.64 ± 9.50    0.944
  After therapy   41.80 ± 10.09   47.64 ± 10.02   0.025^*∗*^
  Δ delta         4.08 ± 1.35     10 ± 2.34       0.025^*∗*^

Data are means ± SD or medians (interquartile ranges). ^*∗*^The differences between renin levels variable for genotypes CC and CT/TT were analyzed by independent *t*-test as appropriate.

###### 

Differences of renin levels (valsartan therapy).

  Variable        Genotypes       *P* value      
  --------------- --------------- -------------- ------
  Early therapy   37.03 ± 6.96    38.76 ± 5.59   0.44
  After therapy   43.67 ± 10.49   47.81 ± 9.02   0.32
  Δ delta         6.64 ± 1.25     9.05 ± 3.44    0.40

Data are means ± SD or medians (interquartile ranges). The differences between renin levels variable for genotypes CC and CT/TT were analyzed by independent *t*-test as appropriate.

###### 

Genetic variants of the *REN* and reduction in blood pressure (valsartan therapy).

  *REN* C-5312T   SBP (mmHg)       *P*            DBP (mmHg)   *P* ^**∗**^                   
  --------------- ---------------- -------------- ------------ --------------- ------------- ------
  CT/TT           155.2 ± 15.3     135 ± 13.6     0.56         93.20 ± 15.5    83.2 ± 13.6   0.04
  CC              140.65 ± 19.03   120.5 ± 20.5                92.45 ± 15.23   80.1 ± 14.6    

Data are means ± SD. Statistical analysis of the difference was performed by independent *t*-test as appropriate. ^*∗*^ *P* value was calculated for the statistics showing the interactive effect of ARB administration and category in patients on DBP.

###### 

Genetic variants of the *REN* and reduction in blood pressure (telmisartan therapy).

  *REN* C-5312T   SBP (mmHg)     *P*            DBP (mmHg)   *P* ^*∗*^                     
  --------------- -------------- -------------- ------------ --------------- ------------- ------
  CT/TT           150.5 ± 18.4   130.5 ± 13.6   0.66         90.20 ± 15.5    82.2 ± 15.4   0.03
  CC              145.7 ± 17.9   125 ± 20.5                  92.45 ± 15.23   80.1 ± 15.6    

Data are means ± SD. Statistical analysis of the difference was performed by independent *t*-test as appropriate. ^*∗*^ *P* value was calculated for the statistics showing the interactive effect of ARB administration and category in patients on DBP.

###### 

Difference of renin levels based on salt intake.

  Salt diet   Baseline renin levels   *P* value
  ----------- ----------------------- -----------
  No (19)     33.5 ± 7.84             0.021
  Yes (36)    40.4 ± 8.64             

Data are means ± SD or medians (interquartile ranges). ^*∗*^The differences between renin levels variable for salt and nonsalt diet hypertensive patients were analyzed by independent *t*-test as appropriate.

###### 

Difference of renin levels based on genotype in salt diet patients.

  Genotype     Baseline levels renin   *P* value
  ------------ ----------------------- -----------
  CT/TT (13)   39.5 ± 8.84             0.027
  CC (7)       33.4 ± 7.34             

Data are means ± SD or medians (interquartile ranges). ^*∗*^The differences between renin levels variable for genotypes CC and CT/TT were analyzed by independent *t*-test as appropriate.
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